Navigation Links
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
Date:12/17/2010

BRISBANE, Calif., Dec. 17, 2010 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced additions to its senior leadership team to prepare for the commercialization of Esbriet™ (pirfenidone) in Europe.  InterMune's Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "We are very pleased by the high quality of candidates who are interested in joining our European organization which will be headquartered in Basel, Switzerland.  The individuals announced today are very accomplished and seasoned pharmaceutical executives who will be the part of our team that will prepare our organization to successfully launch Esbriet in Europe.  We will continue to move quickly to prepare to launch the first approved therapy in Europe in adults for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF)."

EU Leadership Appointments

InterMune announced the following additions to its leadership team:

  • Senior Vice President and Managing Director, Europe Giacomo Di Nepi.  Mr. Di Nepi joined InterMune in this role in November of 2009.  Before Joining InterMune he was Chief Executive Officer of Takeda Pharmaceuticals Europe, where he drove the EU operations and geographic expansion.  Prior to that, Mr. Di Nepi was a member of the Executive Committee of Novartis Pharma AG as Global Head for the Transplantation and Infectious Disease business unit.  He previously served as Chief Executive Officer of Novartis Italy.  Before entering the pharmaceutical industry, he was a partner in the healthcare practice of McKinsey & Co.  Mr. Di Nepi will be based i
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune to Release Third Quarter Financial Results on October 28
2. InterMune Sells Danoprevir Rights to Roche for $175 Million
3. InterMune to Present at 2010 Citi Health Care Conference
4. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
5. InterMune to Release First Quarter Financial Results on April 29
6. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
7. InterMune Announces Proposed Public Offering of Common Stock
8. InterMune to Release Third Quarter Financial Results on November 5
9. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
10. InterMune to Present at Canaccord Adams Conference
11. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 WIRB-Copernicus Group ® ("WCG")™, ... review services for clinical research, announced today that ... of Richmond, VA -based Alliance ... biosecurity consulting firm in the United ... division – WCG Biosafety™ – will be able ...
(Date:7/24/2014)... Canada (PRWEB) July 24, 2014 The ... Optimizing Dose Escalation in First in Human Studies” will ... make better go/no-go decisions. , With increasing R&D costs ... pharmaceutical companies need to maximize the knowledge collected in ... decisions and improve success in late stage development. , ...
(Date:7/24/2014)... 24, 2014  Spherix Incorporated (SPEX) -- an intellectual ... of intellectual property, today announced that the Company will ... 30, 2014 on Monday, August 18, 2014 for shareholders. ... ET on Monday, August 18, 2014 to discuss the ... company,s CEO, Anthony Hayes . Following ...
(Date:7/24/2014)... 24, 2014 As part of the ... in the MENA region during 2014 with potential global ... provider agreement with DZS to manage our clinical trials ... Global VP of R&D and President of SBI pharmaceuticals ... operational practices with a focus on utilizing eClinical software ...
Breaking Biology Technology:WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the "Company") ... in a Phase 1b clinical trial of PX-12 ... proprietary small molecule,inhibitor of thioredoxin, a protein that ... survival and drug resistance of,many cancers., The ...
... and present a poster on proprietary siRNA ... targeting and ... Pharmaceuticals, Inc., a,development-stage pharmaceutical company discovering and developing novel,RNA ... Cambridge Healthcare Institute,s 9th Annual Beyond,Genome Conference on June ...
... Calif., June 10 DURECT Corporation,(Nasdaq: DRRX ... (NDA) for,Remoxy(TM) (ORADUR(TM)-based oxycodone) has been submitted to ... investigational drug, is a long,acting oral formulation of ... on DURECT,s ORADUR technology, Remoxy is designed to ...
Cached Biology Technology:Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 2Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5
(Date:7/24/2014)... This news release is available in German . ... that there are 300 million asthma sufferers worldwide, a ... up to 30% of the global population contending with ... inflammatory diseases can also affect other organs and parts ... occur in the intestine (in the form of inflammatory ...
(Date:7/24/2014)... news release is available in German . ... welcomed in Norway and they are a common sight on ... that electric cars topped the list of new vehicle registrations ... the situation in Germany, where electric vehicles claim only a ... on the roads in Germany, only a mere 8000 are ...
(Date:7/24/2014)... in German . ... respond to threats to health, and to provide life-long ... the mechanism underlying immunologic memory, however, has remained elusive. ... support the hypothesis that the persistence of immune memory ... potential. Until now, there was no conclusive evidence, largely ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3
... 2011 With millions of people warding off winter,s ... raising red flags about the potential health effects of ... in the American Chemical Society,s (ACS,) journal, Chemical ... inhaled into the lungs from wood smoke may have ...
... Darwin, the "tree of life" has been the preeminent metaphor ... changing of individual species. The discovery that a large ... species of fungus to another, however, significantly strengthens the argument ... more appropriate. "The fungi are telling us something important ...
... reports that family mealtimes that contain three ingredients in the ... who have chronic asthma. "Family mealtimes, when they,re done ... reduced risk of substance abuse, eating disorders, and obesity. In ... we can see minute by minute which factors deliver these ...
Cached Biology News:Discovery of jumping gene cluster tangles tree of life 2Discovery of jumping gene cluster tangles tree of life 3Recipe for family mealtimes calls for 3 ingredients in the right amounts 2
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Biology Products: